In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019

Yazar: Klippel, Zandra, Kimball, Amy, Tekle, Christina
Yayımlandı Blood Cancer J (2019)

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

Yazar: Li, Yanli, Klippel, Zandra, Shih, Xiaolong, Wang, Hong, Reiner, Maureen, Page, John H.
Yayımlandı Cancer Chemother Pharmacol (2016)

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

Yazar: Li, Yanli, Family, Leila, Chen, Lie H., Page, John H., Klippel, Zandra, Xu, Lanfang, Chao, Chun R.
Yayımlandı Cancer Med (2018)

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

Yazar: Klippel, Zandra K., Chou, Jeffrey, Towlerton, Andrea M., Voong, Lilien N., Robbins, Paul, Bensinger, William I., Warren, Edus H.
Baskı/Yayın Bilgisi 2014

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer

Yazar: Nordstrom, Beth L., Simeone, Jason C., Malley, Karen G., Fraeman, Kathy H., Klippel, Zandra, Durst, Mark, Page, John H., Xu, Hairong
Yayımlandı Front Oncol (2016)

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

Yazar: Dale, David C., Crawford, Jeffrey, Klippel, Zandra, Reiner, Maureen, Osslund, Timothy, Fan, Ellen, Morrow, Phuong Khanh, Allcott, Kim, Lyman, Gary H.
Yayımlandı Support Care Cancer (2017)

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous...

Yazar: Cowan, Andrew J., Klippel, Zandra K., Stevenson, Philip A., Hyun, Teresa S., Tuazon, Sherilyn, Becker, Pamela S., Green, Damian J., Holmberg, Leona A., Coffey, David G., Gopal, Ajay K., Libby, Edward N.
Yayımlandı Amyloid (2016)

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

Yazar: Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Yayımlandı Cancer Med (2020)

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Yazar: Facon, Thierry, Niesvizky, Ruben, Mateos, Maria-Victoria, Siegel, David, Rosenbaum, Cara, Bringhen, Sara, Weisel, Katja, Ho, P. Joy, Ludwig, Heinz, Kumar, Shaji, Wang, Kenneth, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra, Mezzi, Khalid, Goldrick, Amanda, Tekle, Christina, Dimopoulos, Meletios A.
Yayımlandı Blood Adv (2020)